J0882
J0882 – Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 14 NDCs crosswalked per 1 MCG $2.920/unit ASP+6%
📋 J0882 summary
J0882 is a HCPCS Level II J-code used to bill darbepoetin alfa, 1 microgram (for esrd on dialysis), billed per 1 MCG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J0882: Aranesp(J0882), Aranesp
Code J0882
Billing unit 1 MCG Payment limit $2.920/unit NDC-Crosswalk 14
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ0882
DescriptorInjection, darbepoetin alfa, 1 microgram (for esrd on dialysis)
Billing unit1 MCG
Payment limit / unit$2.920
Est. ASP / unit$2.755 est.
Mapped NDCs14
Data periodQ3 2026
Last updated2026-08-20
💊 About Darbepoetin Alfa Injection DRUG GUIDE
Aranesp (darbepoetin alfa) injection is used to treat anemia — a low red blood cell count — in two main groups of patients.
It is approved for adults and children (1 month and older) with chronic kidney disease (CKD), whether or not they are on dialysis.Aranesp is also approved to treat anemia caused by myelosuppressive chemotherapy (cancer treatment that suppresses the bone marrow) in adults with non-myeloid cancers, when at least two more months of chemotherapy are planned.
It is not approved to cure anemia quickly, as a substitute for a blood transfusion when immediate correction is needed, or for cancer patients whose treatment goal is a cure.
Clinical overview from our editorial drug guide for Darbepoetin Alfa Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$2.920
Est. ASP / unit
$2.755 est.
Est. after 2% sequester
$2.862
HCPCS dosage
1 MCG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, darbepoetin alfa, 1 microgram (for esrd on dialysis)
CoverageD — Special coverage instructions apply
Pricing indicator57
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2017-01-01
Date added2006-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J0882 = 1 mcg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J0882 LEAST EXPENSIVE FIRST
14 NDCs map to J0882. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($2.920/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 55513-0002-04 | ARANESP darbepoetin alfa 25 ug/mL SOLUTION | Amgen, | 4 VIAL, SINGLE-DOSE in 1 PACKAGE (55513-00... | 25 ug/mL | 100 | $292.00 | $185.363 | ● Active | CMS ASP |
| 55513-0057-04 | ARANESP darbepoetin alfa 25 ug/.42mL INJECTION, SOLUTION | Amgen, | 1 BLISTER PACK in 1 PACKAGE (55513-057-04)... | 25 ug/.42mL | 100 | $292.00 | $447.048 | ● Active | CMS ASP |
| 55513-0021-04 | ARANESP darbepoetin alfa 40 ug/.4mL INJECTION, SOLUTION | Amgen, | 1 BLISTER PACK in 1 PACKAGE (55513-021-04)... | 40 ug/.4mL | 160 | $467.20 | $752.436 | ● Active | CMS ASP |
| 55513-0023-04 | ARANESP darbepoetin alfa 60 ug/.3mL INJECTION, SOLUTION | Amgen, | 1 BLISTER PACK in 1 PACKAGE (55513-023-04)... | 60 ug/.3mL | 240 | $700.80 | $1,501.160 | ● Active | CMS ASP |
| 55513-0003-04 | ARANESP darbepoetin alfa 40 ug/mL SOLUTION | Amgen, | 4 VIAL, SINGLE-DOSE in 1 PACKAGE (55513-00... | 40 ug/mL | 160 | $467.20 | — | ● Active | CMS ASP |
| 55513-0004-04 | ARANESP darbepoetin alfa 60 ug/mL SOLUTION | Amgen, | 4 VIAL, SINGLE-DOSE in 1 PACKAGE (55513-00... | 60 ug/mL | 240 | $700.80 | — | ● Active | CMS ASP |
| 55513-0005-04 | ARANESP darbepoetin alfa 100 ug/mL SOLUTION | Amgen, | 4 VIAL, SINGLE-DOSE in 1 PACKAGE (55513-00... | 100 ug/mL | 400 | $1,168.00 | — | ● Active | CMS ASP |
| 55513-0006-01 | ARANESP darbepoetin alfa 200 ug/mL SOLUTION | Amgen, | 1 VIAL, SINGLE-DOSE in 1 PACKAGE (55513-00... | 200 ug/mL | 200 | $584.00 | — | ● Active | CMS ASP |
| 55513-0025-04 | ARANESP darbepoetin alfa 100 ug/.5mL INJECTION, SOLUTION | Amgen, | 1 BLISTER PACK in 1 PACKAGE (55513-025-04)... | 100 ug/.5mL | 400 | $1,168.00 | — | ● Active | CMS ASP |
| 55513-0027-04 | ARANESP darbepoetin alfa 150 ug/.3mL INJECTION, SOLUTION | Amgen, | 1 BLISTER PACK in 1 PACKAGE (55513-027-04)... | 150 ug/.3mL | 600 | $1,752.00 | — | ● Active | CMS ASP |
| 55513-0028-01 | ARANESP darbepoetin alfa 200 ug/.4mL INJECTION, SOLUTION | Amgen, | 1 BLISTER PACK in 1 PACKAGE (55513-028-01)... | 200 ug/.4mL | 200 | $584.00 | — | ● Active | CMS ASP |
| 55513-0032-01 | ARANESP darbepoetin alfa 500 ug/mL INJECTION, SOLUTION | Amgen, | 1 BLISTER PACK in 1 PACKAGE (55513-032-01)... | 500 ug/mL | 500 | $1,460.00 | — | ● Active | CMS ASP |
| 55513-0098-04 | ARANESP darbepoetin alfa 10 ug/.4mL INJECTION, SOLUTION | Amgen, | 1 BLISTER PACK in 1 PACKAGE (55513-098-04)... | 10 ug/.4mL | 40 | $116.80 | — | ● Active | CMS ASP |
| 55513-0111-01 | ARANESP darbepoetin alfa 300 ug/.6mL INJECTION, SOLUTION | Amgen, | 1 BLISTER PACK in 1 PACKAGE (55513-111-01)... | 300 ug/.6mL | 300 | $876.00 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$25.4K
Claims
68
Beneficiaries
42
Spend / beneficiary
$605.43
Spend / claim
$373.94
Trend by period
Where J0882 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #638 of 824
#633
MODERNA COVID (6M-1... 91321
$30.1K
#634
MEROPENEM(J2185) J2185
$28.1K
#635
CYGNUS, PER SQ CM** Q4170
$28K
#636
CROMOLYN SODIUM J7631
$27.6K
#637
LINCOCIN* J2010
$27.1K
#638
ARANESP(J0882) J0882
$25.4K
#639
VINCASAR PFS* J9370
$24.6K
#640
HYPERHEP B* 90371
$24.3K
#641
ENOXAPARIN SODIUM* J1650
$24.3K
#642
METHOTREXATE SODIUM* J9260
$24.2K
#643
PROCAINAMIDE HCL J2690
$24.1K
Total claims — #669 of 824
#664
ALKERAN* J9245
70
#665
NAFCILLIN SODIUM J2290
69
#666
ENGERIX-B PEDIATRIC-... 90744
68
#667
LUMIZYME J0221
68
#668
BUSULFAN* J0594
68
#669
ARANESP(J0882) J0882
68
#670
POMBILITI J1203
68
#671
ELAPRASE J1743
68
#672
ADZYNMA J7171
68
#673
OASIS BURN MATRIX** Q4103
68
#674
RIXUBIS J7200
65
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $25.4K | 42 | 68 | $605.43 | $373.94 |
| 2025 (Q1-Q4) | $164.3K | 171 | 365 | $960.66 | $450.06 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$110.6K
Medicare paid
$85.6K
Submitted services
51,934
Denial rate
27.9%
Allowed / service
$2.95
Submitted charges
$723.1K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
14 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J0882 billing FAQ
What is HCPCS code J0882?
J0882 is a HCPCS Level II J-code used to bill Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0882?
One unit of J0882 represents 1 MCG. Report the number of units equal to the dose administered divided by 1 MCG.
How many units of J0882 should I bill?
Divide the dose administered by the code's unit size (1 MCG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0882?
The Medicare Part B payment limit is $2.920 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $2.862 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0882?
14 NDCs currently map to J0882 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0882 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.